Colorectal cancer is a major problem for public health worldwide because of its frequency and its severity. Many efforts have been carried to target the vascular endothelial growth factor (VEGF) pathway, one of the main promoters of pathological angiogenesis. Therapeutic monoclonal antibodies against VEGF have emerged as essential biopharmaceuticals for the advanced stages of the disease, in association with appropriate backbone chemotherapy. Unfortunately, after an initial benefit for the patients, resistance invariably develops. These mechanisms of resistance are largely studied and recent publications indicate that the interleukin (IL)-17/IL-17 receptor (IL-17R)A axis could be a key player in the pathological progression. In this mini review, we present evidence for IL-17A/IL-17RA axis targeting in colorectal cancer to improve efficiency of anti-VEGF therapy and to implement a new therapeutic strategy.
Introduction
Colorectal cancer is a major problem for public health around the world because of its frequency and its severity. [1] [2] [3] CRC is the second cause of cancer-related death in Europe and in the United States and the third cause worldwide. Most deaths are due to metastases, which are mainly located in the liver. Approximately 90% of new cases and deaths occur in individuals aged 50 years and older. The understanding of signaling pathways and their molecular mechanisms in CRC allowed the development of targeted therapies besides conventional chemotherapy. 4 To date, a total of 4 mAbs, 1 fusion protein and 1 tyrosine kinase inhibitor are approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to fight against mCRC when associated with appropriate backbone chemotherapy:
Monoclonal antibodies targeting epidermal growth factor receptor mAbs: cetuximab (Erbitux; Eli Lilly and Co) and panitumumab (Vectibix; Amgen Inc). Monoclonal antibodies targeting VEGF and its receptor VEGFreceptor 2 (VEGF-R2): bevacizumab (Avastin; Genentech) and ramucirumab (Cyramza; Eli Lilly and Co), respectively. A fusion protein targeting VEGF-A, VEGF-B, and placental growth factor: VEGF-trap/aflibercept (Zaltrap; Regeneron Pharmaceuticals, Inc). Tyrosine kinase inhibitor of VEGF signaling pathways: regorafenib (Stivarga; Bayer).
Because VEGF/VEGF-R2 is a key signaling pathway implicated in angiogenesis, anti-VEGF therapies, primarily directed against endothelial cells, have been assumed to be very promising in cancer treatment and to present a low risk of resistance. 5 Despite the initial efficacy of drugs targeting tumor angiogenesis in mCRC, resistance invariably develops. [6] [7] [8] In vitro as well as in vivo studies were carried out to understand the resistance to anti-VEGFs. For instance, Fan et al showed that chronic exposure of CRC cell lines to bevacizumab resulted in increased expression of VEGF family members, and those cells were reported to be more aggressive when injected into mice. 9 Furthermore, prolonged inhibition of VEGF in CRC cell lines caused a resistance to hypoxia-induced apoptosis and an increase of VEGF expression level. 10 Moreover, Mésange et al reported that intrinsic resistance to bevacizumab was accompanied by high levels of VEGF in the tumor microenvironment of xenografted mice. In the same report, the authors also showed that this resistance is accompanied with an activation of hypoxia inducible factor, VEGF-R1 and VEGF-R2 signaling in the tumor cells, and a resistance to hypoxia-induced apoptosis.
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Resistance to drugs targeting tumor angiogenesis in mCRC is at the forefront of research. Multiple molecular mechanisms of resistance have been identified. One is the activation of alternative signaling of key downstream pathways despite sustained inhibition of the original drug target. Interestingly, increasing evidence suggests that resistance to anti-VEGF therapies could be partly due to IL-17/IL-17RA axis. In this mini-review, we present evidence for targeting the IL-17/IL-17RA axis in mCRC to improve current therapies.
Interleukin-17: A New Player in CRC Development

Interleukin-17 Family: A Rapid Overview
The IL-17 family is already well known. 12 Briefly, IL-17A, the most studied ligand of this family, is a proinflammatory cytokine that contributes to the pathogenesis of inflammatory and autoimmune diseases. 13, 14 This soluble factor is also highly associated with cancer progression. 15, 16 A canonical source of IL-17A is a lineage of T cells known as CD4 þ T helper Th17 cells.
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Transforming growth factor-b, IL-6, IL-21, and other factors usually released in the tumor microenvironment are responsible for the induction of Th17 differentiation and IL-23 contributes to sustain the Th17 phenotype. In these cells the production of IL-17A is regulated by transcription factor retinoic orphan receptorgt, which in turn is induced by signal transducer and activator of transcription 3 (STAT3). 18 21 Its signaling occurs through the same receptors as IL-17A, with a better affinity to IL-17RC. 19 
Interleukin-17A: A Possible Prognostic Factor
Strong evidence supports the implication of IL-17 and its downstream signaling in the initiation and progression of CRC. However, the underlying mechanism remains unclear. Previously, Le Gouvello and colleagues 22 have shown an increase of IL-17A intratumor expression in proficient mismatch repair colon cancer (microsatellite stability; poor prognosis phenotype), to which belong most CRCs. 23, 24 IL-17A expression level was reported to be significantly elevated in the tumor environment of CRC from the adenoma stage to the cancer stage. 25 It was also suggested that high IL-17A tissue expression level could be associated with the aggressiveness of CRC and with poor prognosis. 26 In addition, serum levels of IL-17A were reported to be increased in CRC patients 27, 28 and high baseline IL-17A serum concentrations might be associated with shorter progression-free survival in patients with mCRC treated with a bevacizumab-based chemotherapy. 29 Interestingly, this is accompanied by an increased percentage of Th17 cells in the circulation in early stages of CRC, whereas in advanced stages those cells would preferentially infiltrate and accumulate in tumor tissue. 28 Moreover, CRC patients with a low level of IL-17A present a higher 5-year survival rate compared with those with a high level suggesting that the expression level of IL-17A can predict the poor prognosis of human CRC. 26 A clinical study reveals that a high Th17 signature (expression of Th17 clusters of genes IL-17A, retinoic orphan receptor C) in patients with stage I or II CRC reduces disease-free survival after resection of primary tumors. 30 Nevertheless, the tumorigenic role of IL-17A in CRC is not only accomplished by Th17-derived IL-17A. This has been recently proven in a murine study in which a critical tumorigenic requirement for IL-17A generated mainly by gdT cells (and other sources) was reported in mice carrying enterotoxigenic Bacteroides fragilis tumor. 31 Tseng et al reported a positive correlation between the serum level of IL-17A and circulating tumor cells (CTCs) known to cause metastasis, in CRC patients as well as in mice. 32 Furthermore, in the same report, IL17-A depletion with intraperitoneal injection of anti-IL-17A mAbs in mice suppressed the increase of CTCs and prevented metastasis. 32 Taken together, these data suggest that IL-17A could serve as a prognostic marker and a therapeutic target for CRC metastasis.
Mechanisms of Action of IL-17 in Tumorigenesis and Resistance to Anti-VEGF Treatment
An elegant study reported that one of the mechanisms of IL-17A promoting tumorigenesis is exerted by IL-17RA engagement in colonic epithelial cells. Indeed, IL-17RA activates extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase, and nuclear factor-kB signaling pathways within transformed enterocytes and promotes their proliferation in a mouse model causing early tumor development. 33 The protumoral role of IL17A also relies on the surrounding stromal cells. In murine models, Chung and colleagues showed that tumor-infiltrating Th17 cells and IL-17 can activate tumor-associated fibroblasts to secrete granulocyte colony-stimulating factor, which in turn recruits myeloid-derived suppressive cells (MDSCs) to the tumor microenvironment. 34 More precisely, these MDSCs 35 produce angiogenic and immune-suppressive molecules such as VEGF, prokineticin 2/ Bv8, matrix metalloproteinase (MMP)-9 (MMP9) and proinflammatory S100A8/9 molecules (calprotectin), thereby mediating resistance to anti-VEGF treatment. 34 Recruited by Th17 lymphocytes, MDSCs could also lead to a feed-forward effect (loop) by promoting Th17 differentiation and IL-17A production. 36 Notably, MDSCs were reported to be crucial for the development of Th17 through the production of IL-1b, IL-6, IL-23, and nitric oxide in patients with ovarian cancer. 37 Besides, the inflammatory responses driven by IL-17A were proven to be increased in human CRC tissues that show the highest levels of this cytokine compared with adenoma and normal tissues. This was highlighted by the activation of ERK1/2 and c-Jun Nterminal kinase pathways and the increased expression of MMPs (MMP9, MMP7, and MMP2), B-cell lymphoma, and cyclin D1.
Moreover, IL-17 promotes tumorigenesis indirectly by inducing IL-6 production by tumor and surrounding stromal cells (mainly fibroblasts and endothelial cells), which activates STAT3, an oncogenic signal transducer and activator of transcription, resulting in upregulation of survival and proangiogenic genes. 39 Further, a significant correlation between intratumor expression of IL-17 and VEGF has been reported using immunohistochemical staining of tissues from 52 CRC patients. 26 These studies confirm the proangiogenic role of IL-17A shown for the first time by Numasaki et al, who indicated that locally secreted IL-17 by tumors promotes angiogenesis and thereby enhances tumor growth in mouse models. 40 A recent study has shown that a membrane bound form of IL-17A expressed in a CRC cell line (CT26), which binds strongly and stably to the IL-17A receptor, enhances cell cycle progression and tumorigenesis. 41 The mechanisms of action of IL-17A as described previously are illustrated in Figure 1 .
Interleukin-17 Axis: The Antitumoral Side
Despite the strong evidence of IL-17A protumoral role, an antitumoral side of IL-17A was reported in some studies. Interestingly, gastric adenocarcinoma patients with high IL-17 intratumoral expression showed significantly higher 5-year survival rates than those with lower IL-17 expression. 42 Moreover, IL-17 participates in the reduction of tumor growth as well as metastasis in a syngeneic MC38 CRC model. 43 The antitumor function of IL-17 is generated by enhancing natural killer cells and cytotoxic T lymphocyte activation, mainly through the recruitment of neutrophils, natural killer cells and T cells to tumor. These antitumoral mechanisms have already been nicely reviewed elsewhere. 18, 44 It is worth noting that IL-17F is reported to exert an anticancer effect. 45 Interestingly, it was shown that IL-17F is downregulated throughout tumorigenesis in human CRC tissues and its expression suppressed CRC tumor progression in mice. 46 An explanation of the different functions and amounts of IL-17A and IL-17F in the tumor milieu could be partly attributable to the high plasticity of their main producer, the Th17 cell lineage that has quite recently broken the Th1/Th2 paradigm. The dynamic balance between Th17 and Th1 or between Th17 and T regulatory cells is crucial for tumor progression/regression and depends on local oncoinflammatory stimuli and cell-cell interactions. These CD4 þ lineages are especially subject to reciprocal transdifferentiation or reverse plasticity. The review by Ye et al emphasizes characteristics of Th17 plasticity and Th17 heterogeneity in tumor immunity. 47 
Implication of the Polymorphisms of IL-17
The effect of single nucleotide polymorphisms of IL-17A gene on inflammatory bowel diseases risk has been shown in several studies. 48, 49 Moreover, ulcerative colitis has been associated with subsequent development of CRC. 50 This suggested the possible implication of IL-17A polymorphisms in CRC risk. Many studies and meta-analyses have been carried out to clarify the effects of IL-17A G197A (rs2275913) and IL-17F T7488C (rs763780) polymorphisms on cancer risk. The rs2275913 polymorphism correlates with more efficient IL-17A secretion and enhances IL-17-mediated immune responses 51 whereas the rs763780 polymorphism causes a histidine to arginine substitution at amino acid 161 (H161R) which antagonizes the function of wild type IL-17F. 52 These polymorphisms might be relevant for digestive cancers because several studies reported an association between IL-17 polymorphisms and an increased risk of gastric cancer. [53] [54] [55] [56] Dai et al showed in a metaanalysis that IL-17A rs2275913 as well as IL-17F rs763780 polymorphisms increase the risk of cancer development. 57 Iranian 58 and Tunisian 59 case-control studies showed that IL-17A polymorphisms were associated with increased risk of CRC development. A recent meta-analysis showed the association of the IL-17A polymorphisms with an increased risk of cancer in Asian populations, especially cervical cancer, breast cancer, and ovarian cancer. 60 Few data exist from patients in Europe or in Western countries on the association of these polymorphisms with the risk of CRC. Hence, more studies are needed to clarify whether IL-17A polymorphisms might be used as a diagnostic biomarker of CRC regarding ethnicities.
Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis
All the proof described previously make IL-17A one the most promising targets in CRC. However, for now therapeutic biopharmaceuticals inhibiting IL-17 signaling are only developed and investigated in immune-mediated disorders (inflammatory and autoimmune diseases) such as psoriasis 61 and rheumatoid arthritis. Table 1 .
Secukinumab (Cosentyx; Novartis Pharmaceuticals Corp), also known as AIN457, is a fully human immunoglobulin (Ig)G1k mAb targeting IL-17A. 63 It is the first antieIL-17A approved by the FDA for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis and administered using subcutaneous injection. Ixekizumab (Talz; Eli Lilly and Co) is a humanized IgG4 mAb neutralizing IL-17A. It has been approved by the FDA and EMA for the treatment of plaque psoriasis (phase III clinical trials). 64 Finally, brodalumab (Lumicef; Amgen Inc) is a fully human IgG2 mAb that binds with high affinity to IL-17RA and thereby it blocks the biological activity of IL-17A/F and IL-17E signaling through this receptor. It has been approved for the treatment of moderate to severe plaque psoriasis (phase III comparative trials).
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Targeting IL-17A has become the focus of preclinical studies in other types of cancer. For example, the administration of AIN457/ secukinumab (see Table 1 ) to mice carrying human myeloma reduced bone damage and significantly inhibited tumor growth compared with isotype-administered control mice. 66 Similarly, the treatment of mice bearing breast cancer with antieIL-17A antibodies decreased the production of programmed death ligand 1 in the tumor microenvironment, promoted the secretion of interferon gamma by CD4 þ and CD8 þ T cells, and decreased the tumor infiltration by regulatory T cells, thereby, antieIL-17A enhances the adaptive immune response in the tumor microenvironment. 67 
Conclusion
Angiogenesis is a complex process in which lots of actors take part. Normalizing tumor vessels or inducing tumor regression remains a challenging task in all cancer types. Therapeutic schedules including mAbs associated with chemotherapy backbone lead most of the time to mechanisms of resistance and tumor escape. Thus the development of combined strategies, associated with relevant biomarkers of response, is of high priority. The IL-17A/IL-17RA axis is a promising target but the mechanisms of action in CRC are not fully understood and need further consideration. In this context, targeting the IL-17/IL-17RA axis in mCRC along with the VEGF pathway could represent a nonnegligible alternative to explore in future clinical trials.
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